Stock Price Forecast

March 18, 2022


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Recro Pharma Inc chart...

About the Company

Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

Exchange

NASDAQ

Website

www.recropharma.com

$75M

Total Revenue

185

Employees

$92M

Market Capitalization

-8.08

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $REPH News

CoreRx strikes $130M deal to snap up struggling small-molecule specialist Societal CDMO

19d ago, source: FiercePharma

The company also said it expected to incur a net loss of $12.1 million to $13.6 million. Recro Pharma rebranded as Societal CDMO in early 2022, several months after snapping up San Diego-based ...

Best Companies To Short As Nasdaq And Tech Stocks Retreat

3y ago, source: Forbes

Price of Intellicheck Inc compared to its Simple Moving Average Next on the Top Short list is Recro Pharma Inc, a stock that has immense downward momentum against it currently. Factor scores of C ...

Societal CDMO Inc (SCTL)

10mon ago, source: Investing

As of late, it has definitely been a great time to be an investor Recro Pharma, Inc. (NASDAQ:REPH) . The stock has moved higher by 27.8% in the past month, while it is also above... Societal CDMO ...

Why Is Biotech/Pharma Contract Service Provider Societal CDMO Stock Trading Higher On Thursday?

19d ago, source: Business Insider

Privately held CoreRx Inc. will acquire Societal CDMO Inc (NASDAQ ... SCTL shares are up 132.6% at $1.07 on the last check Thursday. Recro Pharma NewsMORE Related Stocks ...

Oncology Pharma Inc ONPH

4d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Nuvectis Pharma, Inc. (NVCT)

16h ago, source: Yahoo Finance

Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...

EFTR eFFECTOR Therapeutics, Inc.

18h ago, source: Seeking Alpha

eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product ...

MEI Pharma Inc MEIP

3d ago, source: Morningstar

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...

Nuvectis Pharma, Inc. (NASDAQ:NVCT) insiders have significant skin in the game with 67% ownership

29d ago, source: Yahoo Finance

one can better assess the future performance of a company If you want to know who really controls Nuvectis Pharma, Inc. (NASDAQ:NVCT), then you'll have to look at the makeup of its share registry.

LUMO Lumos Pharma, Inc.

3d ago, source: Seeking Alpha

Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its primary product candidate LUM-201 is an oral ...

ESSA Pharma Inc

1mon ago, source: CNN

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. It engages in the business of developing small molecule drugs for the treatment of prostate cancer. The company was founded by Marianne D.

Acasti Pharma Inc. Class A

3y ago, source: CNN

Acasti Pharma, Inc. is a biopharmaceutical company, which engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...